vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $109.4M, roughly 1.7× TRICO BANCSHARES ). TRICO BANCSHARES runs the higher net margin — 251.6% vs 13.3%, a 238.3% gap on every dollar of revenue. On growth, TRICO BANCSHARES posted the faster year-over-year revenue change (9.0% vs -1.8%). TRICO BANCSHARES produced more free cash flow last quarter ($127.9M vs $24.6M). Over the past eight quarters, TRICO BANCSHARES 's revenue compounded faster (5.4% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
AMPH vs TCBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $109.4M |
| Net Profit | $24.4M | $33.6M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 42.6% |
| Net Margin | 13.3% | 251.6% |
| Revenue YoY | -1.8% | 9.0% |
| Net Profit YoY | -35.7% | 15.8% |
| EPS (diluted) | $0.51 | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $109.4M | ||
| Q3 25 | $191.8M | $107.6M | ||
| Q2 25 | $174.4M | $103.6M | ||
| Q1 25 | $170.5M | $98.6M | ||
| Q4 24 | $186.5M | $100.4M | ||
| Q3 24 | $191.2M | $99.1M | ||
| Q2 24 | $182.4M | $97.9M | ||
| Q1 24 | $171.8M | $98.5M |
| Q4 25 | $24.4M | $33.6M | ||
| Q3 25 | $17.4M | $34.0M | ||
| Q2 25 | $31.0M | $27.5M | ||
| Q1 25 | $25.3M | $26.4M | ||
| Q4 24 | $38.0M | $29.0M | ||
| Q3 24 | $40.4M | $29.1M | ||
| Q2 24 | $37.9M | $29.0M | ||
| Q1 24 | $43.2M | $27.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 42.6% | ||
| Q3 25 | 13.2% | 43.2% | ||
| Q2 25 | 24.2% | 36.5% | ||
| Q1 25 | 21.9% | 35.8% | ||
| Q4 24 | 24.2% | 38.7% | ||
| Q3 24 | 29.8% | 39.8% | ||
| Q2 24 | 30.3% | 40.0% | ||
| Q1 24 | 27.9% | 38.3% |
| Q4 25 | 13.3% | 251.6% | ||
| Q3 25 | 9.0% | 31.6% | ||
| Q2 25 | 17.8% | 26.6% | ||
| Q1 25 | 14.8% | 26.7% | ||
| Q4 24 | 20.4% | 221.4% | ||
| Q3 24 | 21.1% | 29.3% | ||
| Q2 24 | 20.8% | 29.7% | ||
| Q1 24 | 25.1% | 28.2% |
| Q4 25 | $0.51 | $1.02 | ||
| Q3 25 | $0.37 | $1.04 | ||
| Q2 25 | $0.64 | $0.84 | ||
| Q1 25 | $0.51 | $0.80 | ||
| Q4 24 | $0.74 | $0.88 | ||
| Q3 24 | $0.78 | $0.88 | ||
| Q2 24 | $0.73 | $0.87 | ||
| Q1 24 | $0.81 | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $157.0M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.3B |
| Total Assets | $1.6B | $9.8B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $157.0M | ||
| Q3 25 | $276.2M | $298.8M | ||
| Q2 25 | $231.8M | $314.3M | ||
| Q1 25 | $236.9M | $308.3M | ||
| Q4 24 | $221.6M | $145.0M | ||
| Q3 24 | $250.5M | $320.1M | ||
| Q2 24 | $217.8M | $206.6M | ||
| Q1 24 | $289.6M | $82.8M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.3B | ||
| Q3 25 | $776.7M | $1.3B | ||
| Q2 25 | $757.5M | $1.3B | ||
| Q1 25 | $751.3M | $1.3B | ||
| Q4 24 | $732.3M | $1.2B | ||
| Q3 24 | $727.7M | $1.2B | ||
| Q2 24 | $713.3M | $1.2B | ||
| Q1 24 | $672.4M | $1.2B |
| Q4 25 | $1.6B | $9.8B | ||
| Q3 25 | $1.7B | $9.9B | ||
| Q2 25 | $1.6B | $9.9B | ||
| Q1 25 | $1.6B | $9.8B | ||
| Q4 24 | $1.6B | $9.7B | ||
| Q3 24 | $1.5B | $9.8B | ||
| Q2 24 | $1.5B | $9.7B | ||
| Q1 24 | $1.6B | $9.8B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $133.3M |
| Free Cash FlowOCF − Capex | $24.6M | $127.9M |
| FCF MarginFCF / Revenue | 13.4% | 116.9% |
| Capex IntensityCapex / Revenue | 4.5% | 4.9% |
| Cash ConversionOCF / Net Profit | 1.35× | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $133.3M | ||
| Q3 25 | $52.6M | $45.1M | ||
| Q2 25 | $35.6M | $29.2M | ||
| Q1 25 | $35.1M | $24.5M | ||
| Q4 24 | $29.0M | $109.7M | ||
| Q3 24 | $60.0M | $28.6M | ||
| Q2 24 | $69.1M | $31.8M | ||
| Q1 24 | $55.3M | $25.1M |
| Q4 25 | $24.6M | $127.9M | ||
| Q3 25 | $47.2M | $43.2M | ||
| Q2 25 | $25.0M | $28.2M | ||
| Q1 25 | $24.4M | $22.8M | ||
| Q4 24 | $16.6M | $105.2M | ||
| Q3 24 | $46.2M | $27.3M | ||
| Q2 24 | $63.1M | $30.8M | ||
| Q1 24 | $46.5M | $24.1M |
| Q4 25 | 13.4% | 116.9% | ||
| Q3 25 | 24.6% | 40.2% | ||
| Q2 25 | 14.3% | 27.2% | ||
| Q1 25 | 14.3% | 23.1% | ||
| Q4 24 | 8.9% | 104.8% | ||
| Q3 24 | 24.1% | 27.6% | ||
| Q2 24 | 34.6% | 31.5% | ||
| Q1 24 | 27.1% | 24.4% |
| Q4 25 | 4.5% | 4.9% | ||
| Q3 25 | 2.8% | 1.7% | ||
| Q2 25 | 6.1% | 1.0% | ||
| Q1 25 | 6.3% | 1.7% | ||
| Q4 24 | 6.7% | 4.5% | ||
| Q3 24 | 7.2% | 1.3% | ||
| Q2 24 | 3.3% | 1.0% | ||
| Q1 24 | 5.1% | 1.0% |
| Q4 25 | 1.35× | 3.96× | ||
| Q3 25 | 3.03× | 1.33× | ||
| Q2 25 | 1.15× | 1.06× | ||
| Q1 25 | 1.39× | 0.93× | ||
| Q4 24 | 0.76× | 3.78× | ||
| Q3 24 | 1.48× | 0.98× | ||
| Q2 24 | 1.82× | 1.10× | ||
| Q1 24 | 1.28× | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TCBK
Segment breakdown not available.
